Context Therapeutics and Menarini Group put together clinical trial for breast cancer drug

Mugglehead
By Joseph MortonAug 2, 2022, 5:51 pm237 pts
Context Therapeutics (NASDAQ:CNTX) and the Menarini Group are teaming up on a clinical trial and supply agreement for elacestrant, Menarini’s oral estrogen receptor degrader. The agreement is in support of the company’s upcoming Phase 1b/2 ELONA clinical proof-of-concept trial to evaluate onapristone…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Jungle Boys Opening 1st Arizona Dispensary in Phoenix 36

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.